EpiEndo

Icelandic clinical-stage pharmaceutical company founded in 2014, focusing on the impairment of epithelial barriers. EpiEndo Pharmaceuticals aims to address inflammatory conditions affecting the airway, gastrointestinal tract, and skin by targeting the underlying mechanisms of epithelial barrier dysfunction. The company's research and products are primarily intended for patients suffering from chronic inflammatory diseases.